Category Archives: Orphan Drugs
By Jill Wechsler | Published: July 17, 2014
A potential treatment for sickle cell disease has come through the “valley of death” of early stage development due to support from a collaborative partnership established by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The results of early clinical trials demonstrated sufficient effectiveness in addressing the underlying […]
By Guest Blogger | Published: May 21, 2014
By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
By Guest Blogger | Published: May 12, 2014
by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
By William Looney | Published: May 7, 2014
Pharm Exec’s Brand of the Year award is itself a brand with staying power — our first recipient was Merck’s Gardasil papillomavirus vaccine, which eight years later is still going strong as one of the company’s 10 top-selling products.
By Pharm Exec | Published: March 21, 2014
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Sylvant (siltuximab) for adult patients with multicentric Castleman’s disease.